Melanoma Research Victoria

Source: Cancer Network, July 2019 An ongoing trial of an experimental anti–PD-1 antibody, spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib appears to have a tolerable safety profile and durable objective response rate in previously untreated patients with advanced BRAF V600–mutant melanoma, according to the updated results of COMBI-i (abstract 9531) presented during […]

Read the full story

Source: UPI, July 2019 June 6 (UPI) — Researchers have developed a three-drug combination that may be effective in combating advanced melanoma, a study says. Their work showed a combination of inhibitor drugs that block a form of melanoma known as BRAF V600E, helpeding to extend the lives of people with the disease, according to the […]

Read the full story

Source: Cancer Network, July 2019 An international, randomized, open-label phase III study comparing the efficacy and safety of nivolumab plus bempegaldesleukin—an experimental interleukin (IL)-2–based drug—vs nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma is now enrolling participants. The study design (abstract TPS9601) was presented during a poster session at the 2019 American […]

Read the full story

Source: Healio, July 2019 To improve the rate of melanoma survival, targeted health care interventions are needed for certain patients who experience the most delays in surgical care, according to researchers. “Equalizing the surgical interval for nonwhite patients could be a step in improving melanoma care for all patients, regardless of skin color,” Howa Yeung, MD,assistant […]

Read the full story